Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461550 · ClinicalTrials.gov registry record · NA
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02461550: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02461550 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02461550, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The investigators are investigating the use of a new cancer treatment called Irreversible Electroporation (IRE). This treatment delivers electrical energy between two needles placed in a cancer. The electrical energy causes cells to die. While this has been used in patients for different applications, the investigators are trying to understand how safe and well it works in colon cancer that has spread to the lung. Once the irreversible electroporation procedure is completed during the operation, the surgeon will then remove the cancer according to standard procedure. As part of the study, they will be measuring safety of the electrical energy delivered and will be reviewing the resected specimen under the microscope.
Interventions
- DEVICE Irreversible Electroporation Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02461550
The ClinicalTrials.gov registry entry for NCT02461550 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irreversible Electroporation Ablation is the first listed.
NCT02461550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02461550 about?
NCT02461550 is a clinical study titled "Irreversible Electroporation Ablation for Colorectal Metastases to the Lung". The investigators are investigating the use of a new cancer treatment called Irreversible Electroporation (IRE). This treatment delivers electrical energy between two needles placed in a cancer. The electrical energy causes cells to die. While this has been used in patients for different application...
What is the current status of trial NCT02461550?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-05. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02461550?
The interventions under investigation include: Irreversible Electroporation Ablation (DEVICE).
Who is sponsoring clinical trial NCT02461550?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.